Biohaven (NYSE:BHVN) Raised to “Hold” at Wall Street Zen

Biohaven (NYSE:BHVN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also issued reports on the company. Citigroup reiterated a “buy” rating on shares of Biohaven in a report on Friday, September 18th. HC Wainwright restated a “neutral” rating and set a $10.00 price target on shares of Biohaven in a report on Thursday, September 10th. Robert W. Baird set a $48.00 price target on Biohaven in a report on Thursday. Needham & Company LLC set a $11.00 price target on Biohaven in a research report on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Biohaven in a research note on Friday, June 26th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Biohaven currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.25.

Biohaven Price Performance

Biohaven stock opened at $13.89 on Friday. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23. Biohaven has a 52-week low of $7.48 and a 52-week high of $18.57. The firm has a market cap of $2.10 billion, a PE ratio of -2.99 and a beta of 1.35. The company’s 50 day moving average is $13.51 and its two-hundred day moving average is $12.72.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, research analysts expect that Biohaven will post -3.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Biohaven

Large investors have recently modified their holdings of the company. BlueCrest Capital Management Ltd purchased a new stake in shares of Biohaven during the 2nd quarter worth $60,000. Sterling Capital Management LLC increased its holdings in Biohaven by 847.5% in the third quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock valued at $59,000 after buying an additional 3,975 shares during the last quarter. IFP Advisors Inc increased its holdings in Biohaven by 43.3% in the second quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock valued at $89,000 after buying an additional 1,816 shares during the last quarter. Allworth Financial LP purchased a new position in Biohaven in the second quarter valued at $117,000. Finally, Essential Partners LLC raised its stake in Biohaven by 31.7% in the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after buying an additional 2,169 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven News Roundup

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: FDA review removes a key regulatory hurdle. The FDA accepted Biohaven’s resubmitted application, meaning the agency will conduct a formal review of Vyglxia. A regulatory decision is expected in the first quarter of 2027. Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
• Positive Sentiment: Investors are reassessing the drug’s commercial potential. Coverage highlighted the possibility that approval could give Biohaven a significant new growth opportunity in a rare neurological disease, helping explain the stock’s unusually large advance and some analyst price-target increases. Biohaven Soars 25% on FDA Drug Review, Price Target Upgrade
• Positive Sentiment: Trading activity reinforced the bullish move. Investors purchased 6,072 BHVN call options, approximately 155% above typical daily call volume, signaling heightened speculative interest in further upside. Why Biohaven catapulted 30%-plus and why it might not be done sprinting
• Neutral Sentiment: The FDA has accepted the application for review—not approved Vyglxia. The upcoming review creates a major catalyst, but the outcome remains uncertain and the company still faces the time and expense of completing the regulatory process. Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission
• Negative Sentiment: Sharp gains increase volatility and profit-taking risk. The stock’s rally appears driven largely by a single regulatory event and options activity, while Biohaven remains an unprofitable biotech. Any negative FDA feedback, delay, or questions about Vyglxia’s efficacy or market opportunity could reverse the move.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.